Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Intensive Care Medicine
Published in: Intensive Care Medicine 6/2015

01-06-2015 | Editorial

Balancing the “humors” in severe sepsis: still a role for extracorporeal therapies?

Authors: Michael Darmon, Sean M. Bagshaw, Lui G. Forni

Published in: Intensive Care Medicine | Issue 6/2015

Login to get access

Excerpt

The mortality and morbidity from severe sepsis continue to be a major global health problem. Although the recent data from the Protocol-Based Care for Early Septic Shock (ProCESS) study showed a lower mortality in severe sepsis than had been demonstrated some 10 years previously, the mortality remains unacceptably high [1, 2]. The pathogenesis of sepsis is complex, leading to the production of a wide range of inflammatory mediators, which propagate the host response to infection leading to the clinical syndrome of septic shock with multi-organ involvement. At present, treatment relies predominantly on source control, adequate early antimicrobials and organ support where necessary with little effective, targeted therapy [3‐5]. …
Literature
1.
Investigators ProCESS, Yealy DM, Kellum JA et al (2014) A randomized trial of protocol-based care for early septic shock. N Engl J Med 370:1683–1693CrossRef
2.
Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377PubMedCrossRef
3.
Parmar A, Langenberg C, Wan L et al (2009) Epidemiology of septic acute kidney injury. Curr Drug Targets 10:1169–1178PubMedCrossRef
4.
Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228PubMedCrossRef
5.
Levy MM, Rhodes A, Phillips GS et al (2014) Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. Intensive Care Med 40:1623–1633PubMedCrossRef
6.
De Vriese AS, Colardyn FA, Philippé JJ et al (1999) Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 10:846–853PubMed
7.
De Vriese AS, Vanholder RC, Pascual M et al (1999) Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? Intensive Care Med 25:903–910PubMedCrossRef
8.
Payen D, Mateo J, Cavaillon JM et al (2009) Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 37:803–810PubMedCrossRef
9.
Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM et al (2013) High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 39:1535–1546PubMedCrossRef
10.
Zhou F, Peng Z, Murugan R, Kellum JA (2013) Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med 41:2209–2220PubMedCentralPubMedCrossRef
11.
Iwagami M, Yasunaga H, Doi K et al (2014) Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis. Crit Care Med 42:1187–1193PubMedCrossRef
12.
13.
Cruz DN, Antonelli M, Fumagalli R et al (2009) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301:2445–2452PubMedCrossRef
14.
Payen DM, Guilhot J, Launey Y et al (2015) Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. doi:10.​1007/​s00134-015-3751-z
15.
Nakamura T, Ebihara I, Shoji H et al (1999) Treatment with polymyxin B-immobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P-selectin, platelet factor 4 and beta-thromboglobulin. Inflamm Res 48:171–175PubMedCrossRef
16.
Nemoto H, Nakamoto H, Okada H et al (2001) Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 19:361–368 (discussion 368–369)PubMedCrossRef
17.
Vincent JL, Laterre PF, Cohen J et al (2005) A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23:400–405PubMedCrossRef
Metadata
Title
Balancing the “humors” in severe sepsis: still a role for extracorporeal therapies?
Authors
Michael Darmon
Sean M. Bagshaw
Lui G. Forni
Publication date
01-06-2015
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 6/2015
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-015-3801-6

Other articles of this Issue 6/2015

Intensive Care Medicine 6/2015 Go to the issue

Original

Visualizing the pressure and time burden of intracranial hypertension in adult and paediatric traumatic brain injury

Original

Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization

What's New in Intensive Care

Myths about critical care echocardiography: the ten false beliefs that intensivists should understand

Correspondence

Use of Type III procollagen measurement as predictor of lung fibroproliferation in ARDS: early measurement for earlier antifibroproliferative therapy?

What's New in Intensive Care

Ten tips for managing critically ill burn patients: follow the RASTAFARI!

Original

Long-term neuropsychological outcomes in children and adolescents after cardiac arrest